Showing 8671-8680 of 9994 results for "".
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- ASDS Elects New Officers and Board Membershttps://practicaldermatology.com/news/20141112-asds_elects_new_officers_and_board_members/2459071/The American Society for Dermatologic Surgery (ASDS) announced the election of Tom Rohrer,
- Promius Pharma Launches Promiseb Topical Cream 60 Gram Optionhttps://practicaldermatology.com/news/20141105-promius_pharma_launches_promiseb_topical_cream_60_gram_option/2459073/Promius Pharma LLC launched Promiseb Topical Cream in a new 60 gram box. This well-regarded non-steroidal cream for the treatment of seborrheic
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- NYAM Academic Research Awards in Dermatology Program Accepting Applicationshttps://practicaldermatology.com/news/20141016-nyam_academic_research_awards_in_dermatology_program_accepting_applications/2459083/The application period is now open for the NYAM Academic Research Awards in dermatology program. Deadline for applications is December 15, 2014. The NYAM Academic Research Awards Program provides funding for residents and early-career dermatologists performing basic science or clinical research re
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- New Data for Topical Nitric Oxide Nanoparticles: Evidence in Animal Model of EDhttps://practicaldermatology.com/news/20141014-new_data_for_topical_nitrous_oxide_nanoparticles_evidence_in_animal_model_of_ed/2459086/Topically applied nitric oxide-releasing nanoparticles (NO-NPs) induced spontaneous erections and increased basal ICP in an animal model of radical prostatectomy. According to findings published in The Journal o
- AmSpa Welcomes Cathy Christensen as Executive Director or Operations and Communicationshttps://practicaldermatology.com/news/20141009-amspa_welcomes_cathy_christensen_as_executive_director_or_operations_and_communications/2459089/Cathy Christensen, former editor of Skin Inc. magazine and conference director for the Face and Body events, is now Executive Director or Operations and Communications of AmpSpa. Christensen said, "I have been honored to have a role in serving the professional skin care industry's profes
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha